Cerebral venous thrombosis. Cerebral infarction due to cerebral venous thrombosis, nonpyogenic
Conditions
Interventions
Intervention 1: Intervention group: Intervention group: Standard treatment is given by injecting intravenous heparin or sub-cutaneous enoxaparin (at a dose of 1 mg per kg) twice a day for 5-10 days. A
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: All patients over 18 years of age who are diagnosed with CVT in imaging
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluating the clinical efficacy of Apixaban vs. Warfarin in patients with cerebral venous thrombosis. Timepoint: 6 months. Method of measurement: Clinical efficacy is measured by calculating the 6-months MRS and the rate of recanalization. Drug side effects are also studied by examining the rate of major bleeding and recurrence of thrombosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of the relationship between 6-months MRS-recanalization-the rate of recurrence of thrombosis and major bleeding with age-sex and each of the risk factors between two drug groups. Timepoint: 6 months. Method of measurement: The relationship of each case of 6-months MRS- recanalization- recurrence of thrombosis and major bleeding with age- sex and each of the risk factors between the two drug groups of apixaban and warfarin is measured. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAfarin Ahmadian
Ahvaz University of Medical Sciences
Outcome results
None listed